Maternal serum ADAM12s in the late first trimester of pregnancies with Trisomy 21

Prenatal Diagnosis

Volumn 28, Issue 5, 2008, Pages 422-424

  Spencer, Kevin ^a   Cowans, Nicholas J ^a   Stamatopoulou, Anastasia ^a  

^a KING GEORGE HOSPITAL   (United Kingdom)

Author keywords

Aneuploidy; Free hCG; Growth factor; PAPP A; Screening

Indexed keywords

ADAM PROTEIN;

ADULT; ARTICLE; BLOOD SAMPLING; BLOOD STORAGE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE MARKER; EMBRYO; FEMALE; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HUMAN; MATERNAL SERUM; MULTICENTER STUDY; PRENATAL SCREENING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; TRISOMY 21;

ADAM PROTEINS; BIOLOGICAL MARKERS; DOWN SYNDROME; FEMALE; HUMANS; MEMBRANE PROTEINS; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PRENATAL DIAGNOSIS;

EID: 41149138421     PISSN: 01973851     EISSN: 10970223     Source Type: Journal    
DOI: 10.1002/pd.1994     Document Type: Article

References (16)

1. Christiansen M, Spencer K, Laigaard J, Cowans NJ, Larsen SO, Wewer UM. 2007. ADAM 12 as a second trimester maternal serum markers in screening for Down's syndrome. Prenat Diagn 27: 611-615.
2. Cowans NJ, Spencer K. 2007. First trimester ADAM 12 and PAPP-A as markers for intrauterine fetal growth restriction through their roles in the insulin-like growth factor system. Prenat Diagn 27: 264-271.
3. Gilpin BJ, Loechel F, Mattei MG, Engvall E, Albrechtsen R, Wewer UM. 1998. A novel, secreted form of human ADAM 12 (meltrin alpha) provokes myogenesis in vivo. J Biol Chem 273: 157-166.
4. Laigaard J, Sorensen T, Frohlich C, et al. 2003. ADAM 12: a novel first-trimester maternal serum marker for Down syndrome. Prenat Diagn 23: 1086-1091.
5. Laigaard J, Christiansen M, Frohlich C, Pedersen BN, Ottesen B, Wewer UM. 2005a. The level of ADAM 12 in maternal serum is an early first-trimester marker of fetal trisomy 18. Prenat Diagn 25: 45-46.
6. Laigaard J, Sorensen T, Placing S, et al. 2005b. Reduction of the disintegrin and metalloprotease ADAM 12 in preeclampsia. Obstet Gynecol 106: 144-149.
7. Laigaard J, Cuckle H, Wewer UM, Christiansen M. 2006a. Maternal serum ADAM12 levels in Down's and Edwards' syndrome pregnancies at 9-12 weeks gestation. Prenat Diagn 26: 689-691.
8. Laigaard J, Spencer K, Christiansen M, et al. 2006b. ADAM 12 as a first trimester maternal serum marker in screening for Down syndrome. Prenat Diagn 26: 973-979.
9. Loechel F, Fox JW, Murphy G, Albrechtsen R, Wewer UM. 2000. ADAM 12 cleaves IGFBP-3 and IGFBP-5 and is inhibited by TIMP-3. Biochem Biophys Res Commun 278: 511-515.
10. Shi Z, Xu W, Loechel F, Wewer UM, Murphy LJ. 2000. ADAM 12, a disintegrin metalloprotease, interacts with insulin-like growth factor-binding protein-3. J Biol Chem 275: 18574-18580.
11. Snijders RJM, Noble P, Sebire N, Souka A, Nicolaides KH. 1998. UK multicentre project on assessment of risk for trisomy 21 by maternal age and fetal nuchal translucency thickness at 10-14 weeks of gestation. Lancet 18: 519-521.
12. Snijders RJM, Sundberg K, Holzgreve W, Henry G, Nicolaides KH. 1999. Maternal age and gestation specific risk for trisomy 21. Ultrasound Obstet Gynaecol 13: 167-170.
13. Spencer K, Nicolaides KH. 2002. A first trimester trisomy 13/trisomy18 risk algorithm combining fetal nuchal translucency thickness, maternal serum free β-hCG and PAPP-A. Prenat Diagn 22: 877-879.
14. Spencer K, Cowans NJ. 2007. ADAM12 as a marker of trisomy 18 in the first and second trimester of pregnancy. J Matern Fetal Neonat Med 20: 645-650.
15. Spencer K, Cowans NJ, Stamatopoulou A. 2007. Maternal serum ADAM 12s as a marker of rare aneuploides in the first or second trimester of pregnancy. Prenat Diagn 27: 1233-1237.
16. Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH. 1999. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free β-human chorionic gonadotropin and pregnancy associated plasma protein - A. Ultrasound Obstet Gynaecol 13: 231-237.